PROGYNY INC (PGNY) Stock Fundamental Analysis
USA - NASDAQ:PGNY - US74340E1038 - Common Stock
19.785 USD
+0.45 (+2.3%)
We assign a fundamental rating of 6 out of 10 to PGNY. PGNY was compared to 101 industry peers in the Health Care Providers & Services industry. PGNY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PGNY has a decent growth rate and is not valued too expensively. These ratings would make PGNY suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
PGNY had a positive operating cash flow in the past year.
In the past 5 years PGNY has always been profitable.
In the past 5 years PGNY always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 6.98%, PGNY belongs to the best of the industry, outperforming 88.12% of the companies in the same industry.
PGNY has a Return On Equity of 10.31%. This is in the better half of the industry: PGNY outperforms 74.26% of its industry peers.
PGNY has a better Return On Invested Capital (10.87%) than 82.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PGNY is in line with the industry average of 9.33%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(10.87%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.98% | ||
| ROE | 10.31% | ||
| ROIC | 10.87% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
With a decent Profit Margin value of 4.28%, PGNY is doing good in the industry, outperforming 74.26% of the companies in the same industry.
PGNY's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 6.18%, PGNY is in the better half of the industry, outperforming 63.37% of the companies in the same industry.
In the last couple of years the Operating Margin of PGNY has grown nicely.
PGNY's Gross Margin of 22.34% is in line compared to the rest of the industry. PGNY outperforms 45.54% of its industry peers.
PGNY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.18% | ||
| PM (TTM) | 4.28% | ||
| GM | 22.34% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
PGNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, PGNY has less shares outstanding
PGNY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 6.94 indicates that PGNY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.94, PGNY belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.94 |
ROIC/WACC1.26
WACC8.66%
2.3 Liquidity
PGNY has a Current Ratio of 2.70. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PGNY (2.70) is better than 83.17% of its industry peers.
PGNY has a Quick Ratio of 2.70. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Quick ratio of 2.70. This is amongst the best in the industry. PGNY outperforms 83.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 |
3. Growth
3.1 Past
PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.35%.
PGNY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.77% yearly.
PGNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.62%.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 38.42% on average per year.
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
3.2 Future
The Earnings Per Share is expected to grow by 32.47% on average over the next years. This is a very strong growth
Based on estimates for the next years, PGNY will show a quite strong growth in Revenue. The Revenue will grow by 8.86% on average per year.
EPS Next Y10.72%
EPS Next 2Y34.66%
EPS Next 3Y31.82%
EPS Next 5Y32.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 33.53, which means the current valuation is very expensive for PGNY.
PGNY's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.42, PGNY is valued a bit more expensive.
The Price/Forward Earnings ratio is 19.14, which indicates a rather expensive current valuation of PGNY.
Based on the Price/Forward Earnings ratio, PGNY is valued a bit cheaper than 65.35% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.94, PGNY is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.53 | ||
| Fwd PE | 19.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PGNY is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, PGNY is valued cheaper than 88.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.94 | ||
| EV/EBITDA | 14.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
PGNY's earnings are expected to grow with 31.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.13
PEG (5Y)N/A
EPS Next 2Y34.66%
EPS Next 3Y31.82%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PGNY (10/20/2025, 11:00:07 AM)
19.785
+0.45 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.25%
Inst Owner Change0.45%
Ins Owners1.34%
Ins Owner Change0.04%
Market Cap1.70B
Analysts80
Price Target29.29 (48.04%)
Short Float %8.65%
Short Ratio6.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-11.77%
Max EPS beat(2)14.63%
EPS beat(4)2
Avg EPS beat(4)-0.31%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)9.53%
EPS beat(12)9
Avg EPS beat(12)48.1%
EPS beat(16)13
Avg EPS beat(16)104.01%
Revenue beat(2)2
Avg Revenue beat(2)2.57%
Min Revenue beat(2)1.96%
Max Revenue beat(2)3.19%
Revenue beat(4)3
Avg Revenue beat(4)1.39%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.46%
Revenue beat(16)8
Avg Revenue beat(16)-0.53%
PT rev (1m)0%
PT rev (3m)7.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.39%
EPS NY rev (1m)2.64%
EPS NY rev (3m)13.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.53 | ||
| Fwd PE | 19.14 | ||
| P/S | 1.37 | ||
| P/FCF | 8.94 | ||
| P/OCF | 8.42 | ||
| P/B | 3.3 | ||
| P/tB | 3.48 | ||
| EV/EBITDA | 14.67 |
EPS(TTM)0.59
EY2.98%
EPS(NY)1.03
Fwd EY5.22%
FCF(TTM)2.21
FCFY11.18%
OCF(TTM)2.35
OCFY11.87%
SpS14.44
BVpS5.99
TBVpS5.68
PEG (NY)3.13
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.98% | ||
| ROE | 10.31% | ||
| ROCE | 14.2% | ||
| ROIC | 10.87% | ||
| ROICexc | 24.96% | ||
| ROICexgc | 28.14% | ||
| OM | 6.18% | ||
| PM (TTM) | 4.28% | ||
| GM | 22.34% | ||
| FCFM | 15.31% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score8
Asset Turnover1.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 293.7% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 250.02% | ||
| Profit Quality | 358.02% | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 | ||
| Altman-Z | 6.94 |
F-Score8
WACC8.66%
ROIC/WACC1.26
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y10.72%
EPS Next 2Y34.66%
EPS Next 3Y31.82%
EPS Next 5Y32.47%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%
EBIT growth 1Y7.81%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year33.19%
EBIT Next 3Y18.12%
EBIT Next 5Y15.38%
FCF growth 1Y14.92%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y19.24%
OCF growth 3Y90.18%
OCF growth 5YN/A